So far, various studies have reported the prognostic value of TSR in different types of BC, for example, in triple-negative BC 30-31, lymph node-negative BC 32, primary operable invasive ductal BC 33, estrogen receptor-positive BC 24, and inflammatory BC 26. This evidence concerns the gene ESR1 and breast cancer.